Dec 30, 2020
MediSieve Receives a £1.6 Million UKRI Grant to Trial its Hyperinflammation Programme
MediSieve announced the receipt of a grant from the UK Research and Innovation (UKRI) to support first-in-man trials of its pivotal IL-6-driven hyperinflammation programme.
LONDON – December 30, 2020 – MediSieve, a biotech company which has developed an innovative blood filtration device, today announced the receipt of a grant from the UK Research and Innovation (UKRI) to support first-in-man trials of its pivotal IL-6-driven hyperinflammation programme.
“For the past few months, we have been focussing exclusively on our IL-6 removal product in order to respond to the pandemic. IL-6 is an “inflammatory cytokine”, a signalling molecule produced by your immune system in response to an infection like COVID-19. In severe cases, an overproduction of IL-6 causes the immune system to overreact, which can cause organ damage and death. The removal of IL-6 from critical patients can prevent this overreaction and thereby improve outcomes,” said Dr Cristina Blanco-Andujar, Chief Technology Officer at MediSieve. “We look forward to advance this new technology that could contribute to the global effort to end the COVID-19 pandemic.”
The COVID programme builds upon MediSieve’s existing IL-6 product, which was developed to help patients suffering from sepsis, cytokine release syndrome, and other hyperinflation conditions. Earlier this year the company has been awarded a COVID-19 Continuity Grant from Innovate UK, which provided extra funding worth £222k for their previously awarded Biomedical Catalyst Grant.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: